ArticleMicromachines2020
Metabolic Switching of Tumor Cells under Hypoxic Conditions in a Tumor-on-a-chip Model.
Article in Micromachines, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
26 citing papers in PubMed, 44 citations in OpenAlex.
- Translational Barriers and AI-Driven Challenges of Microfluidics-Enabled Wearables and Implantable Systems in Personalized Medicine.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Review
- Tumor-on-chip's alliance with molecular pathology against metastatic disease.Journal of biomedical science · 2026Review
- Review
- Cancer-on-a-chip for precision cancer medicine.Lab on a chip · 2025Review
- A closed-loop modular multiorgan-on-chips platform for self-sustaining and tightly controlled oxygenation.Proceedings of the National Academy of Sciences of the United States of America · 2024Article
- GPC3-targeted CAR-T cells expressing GLUT1 or AGK exhibit enhanced antitumor activity against hepatocellular carcinoma.Acta pharmacologica Sinica · 2024Article
- Prototyping in Polymethylpentene to Enable Oxygen-Permeable On-a-Chip Cell Culture and Organ-on-a-Chip Devices Suitable for Microscopy.Micromachines · 2024Article
- From complexity to clarity: unravelling tumor heterogeneity through the lens of tumor microenvironment for innovative cancer therapy.Histochemistry and cell biology · 2024Review
- Selective Targeting of Tumor Cells in a Microfluidic Tumor Model with Multiple Cell Types.Methods in molecular biology (Clifton, N.J.) · 2024Article
- Improving tumor microenvironment assessment in chip systems through next-generation technology integration.Frontiers in bioengineering and biotechnology · 2024Review
- Tumor-on-a-chip models combined with mini-tissues or organoids for engineering tumor tissues.Theranostics · 2024Review
- Breaking the mold: 3D cell cultures reshaping the future of cancer research.Frontiers in cell and developmental biology · 2024Review
- Spatiotemporal dissection of tumor microenvironment via in situ sensing and monitoring in tumor-on-a-chip.Biosensors & bioelectronics · 2023Article
- The Applications and Challenges of the Development ofCellular and molecular bioengineering · 2023Review
- Recent Advances of Organ-on-a-Chip in Cancer Modeling Research.Biosensors · 2022Review
- Biofabrication approaches and regulatory framework of metastatic tumor-on-a-chip models for precision oncology.Medicinal research reviews · 2022Review
- Joint-on-chip platforms: entering a new era of in vitro models for arthritis.Nature reviews. Rheumatology · 2022Review
- Mimicking the Biology of Engineered Protein and mRNA Nanoparticle Delivery Using a Versatile Microfluidic Platform.Pharmaceutics · 2021Article
- Microphysiological systems to study tumor-stroma interactions in brain cancer.Brain research bulletin · 2021Review
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 2 institutions in 2 countries.
Funding
Abstract
Hypoxia switches the metabolism of tumor cells and induces drug resistance. Currently, no therapeutic exists that effectively and specifically targets hypoxic cells in tumors. Development of such therapeutics critically depends on the availability of in vitro models that accurately recapitulate hypoxia as found in the tumor microenvironment. Here, we report on the design and validation of an easy-to-fabricate tumor-on-a-chip microfluidic platform that robustly emulates the hypoxic tumor microenvironment. The tumor-on-a-chip model consists of a central chamber for 3D tumor cell culture and two side channels for medium perfusion. The microfluidic device is fabricated from polydimethylsiloxane (PDMS), and oxygen diffusion in the device is blocked by an embedded sheet of polymethyl methacrylate (PMMA). Hypoxia was confirmed using oxygen-sensitive probes and the effect on the 3D tumor cell culture investigated by a pH-sensitive dual-labeled fluorescent dextran and a fluorescently labeled glucose analogue. In contrast to control devices without PMMA, PMMA-containing devices gave rise to decreases in oxygen and pH levels as well as an increased consumption of glucose after two days of culture, indicating a rapid metabolic switch of the tumor cells under hypoxic conditions towards increased glycolysis. This platform will open new avenues for testing anti-cancer therapies targeting hypoxic areas.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.